1688-4221
1688-4221
S1688-42212024000201210
10.22235/cp.v18i2.3730
Peru
Peru
00
12
2024
00
12
2024
18
2
[
2021
4
2
2
56-70
]
[
2022
13
47-58
]
[
2023
]
[
2019
13
2
2
1-6
]
[
2014
167-76
]
[
2022
28
341-7
]
[
2013
Fifth Edition
]
[
2014
]
[
2023
39
2
2
273-86
]
[
2020
10
224
224
]
[
2022
70
3
3
791-800
]
[
2023
12
1
1
1-28
]
[
2020
12
2
2
384-410
]
[
2020
33
]
[
2023
5
1-23
]
[
2021
62
4
4
1-12
]
[
2023
13
1
1
1-13
]
[
2021
279
131-42
]
[
2022
]
[
2019
16
22
22
]
[
2022
69
]
[
2021
]
[
Cochrane Collaboration
2008
]
[
1990
19-38
]
[
2018
66
7
7
537-45
]
[
2015
36
3
3
533-70
]
[
2020
26
5
5
418-23
]
[
2021
42
4
4
821-30
]
[
2023
47
1
1
]
[
2017
13
1
1
26-45
]
[
2009
89
9
9
873-80
]
[
Prisma-P Group
2015
4
1
1
1-9
]
[
2020
20
1
1
1-12
]
[
2020
35
3
3
672-8
]
[
2017
22
7
7
851-65
]
[
2019
37
2
2
116-28
]
[
2020
27
4
4
394-411
]
[
2022
27
3
3
709-34
]
[
2021
21
1
1
1-10
]
[
1989
57
6
6
1069-81
]
[
2014
2
2
2
446-52
]
[
2002
15
3
3
197-8
]
[
2022
27
1
1
]
[
2018
65
201-11
]
[
2015
27
1
1
103-34
]
[
2015
8
171-80
]
[
2022
17
7
7
1-20
]
[
2021
21
1
1
1-12
]
[
2023
16
1425-37
]
[
2019
11
10
10
1022-8
]